MX2021013943A - Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. - Google Patents

Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.

Info

Publication number
MX2021013943A
MX2021013943A MX2021013943A MX2021013943A MX2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A
Authority
MX
Mexico
Prior art keywords
lag
administration
dosage regimes
bispecific antibody
regimes
Prior art date
Application number
MX2021013943A
Other languages
English (en)
Spanish (es)
Inventor
Michelle Morrow
Fiona Germaschewski
Daniel Gliddon
Kin-Mei Leung
Cristian Gradinaru
Christopher Shepherd
Josefin-Beate Holz
Louis Kayitalire
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of MX2021013943A publication Critical patent/MX2021013943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013943A 2019-05-14 2020-05-14 Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. MX2021013943A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
MX2021013943A true MX2021013943A (es) 2022-01-04

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013943A MX2021013943A (es) 2019-05-14 2020-05-14 Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.

Country Status (12)

Country Link
US (1) US20220275092A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969477A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022533578A (cg-RX-API-DMAC7.html)
KR (1) KR20220008316A (cg-RX-API-DMAC7.html)
CN (1) CN114206939A (cg-RX-API-DMAC7.html)
AU (1) AU2020275209A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022831A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139003A1 (cg-RX-API-DMAC7.html)
IL (1) IL287979A (cg-RX-API-DMAC7.html)
MX (1) MX2021013943A (cg-RX-API-DMAC7.html)
SG (1) SG11202112136RA (cg-RX-API-DMAC7.html)
WO (1) WO2020229626A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
CN118165116A (zh) * 2021-03-31 2024-06-11 美勒斯公司 新型多特异性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ-スター セラピューティクス リミテッド Pd-l1及びlag-3に結合する結合分子
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors

Also Published As

Publication number Publication date
SG11202112136RA (en) 2021-11-29
WO2020229626A1 (en) 2020-11-19
US20220275092A1 (en) 2022-09-01
JP2022533578A (ja) 2022-07-25
IL287979A (en) 2022-01-01
EP3969477A1 (en) 2022-03-23
KR20220008316A (ko) 2022-01-20
BR112021022831A2 (pt) 2022-01-18
CN114206939A (zh) 2022-03-18
CA3139003A1 (en) 2020-11-19
AU2020275209A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
BR112021022831A2 (pt) Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SA523440623B1 (ar) أجسام مضادة
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
PH12022551960A1 (en) Antibodies binding to b7h4
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
Mannas et al. Long-term treatment with temozolomide in malignant glioma
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
Morris et al. Results of a 5-week schedule of modern total skin electron beam radiation therapy
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
PH12022551021A1 (en) Sequential anti-cd19 therapy
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2021005266A (es) Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer.
Jagannath et al. Pomalidomide (POM) with low-dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide (LEN) and bortezomib (BORT): updated phase 2 results and age subgroup analysis
Auer et al. R2W: subcutaneous bortezomib, cyclophosphamide and rituximab (BCR) versus fludarabine, cyclophosphamide and rituximab (FCR) for initial therapy of Waldenstrőm’s macroglobulinemia: a randomised phase II study
MX2023007178A (es) Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
Dos Santos et al. Anti-leukemic activity of daratumumab in acute myeloid leukemia cells and patient-derived xenografts
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
Serre et al. Brachytherapy: Perspectives for combined treatments with immunotherapy
JOP20230112A1 (ar) أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
Lachota et al. Dasatinib effect on NK Cells and anti-tumor immunity